

Kendle international inc.

Finance



Kendle International Inc.

Kendle is involved in contractual research for companies. Kendle is basically a clinical research organization, and it provides services from Phase I-IV of clinical development to bigger pharma companies. Kendle delivers integrated clinical research services, including clinical trial management, clinical data management, statistical analysis, medical writing, regulatory consulting and organizational meeting management and publications services on a contract basis to the pharma industry. Kendle operates in North America, Europe, Asia/Pacific, Latin America and Africa. On August 16, 2006, Kendle completed the acquisition of Phase II-IV Clinical Services business of Charles River Laboratories International, Inc. In April 2006, Kendle acquired CRO International Clinical Research Limited.

The current financials of Kendle are as follows:

(In millions of USD)

Income Statement

Quarterly

(Jun '06)

Annual

(2005)

Annual

(2004)

Total Revenue

81. 92

250. 64

<https://assignbuster.com/kendle-international-inc/>

215. 87

Gross Profit

28. 13

93. 45

75. 98

Operating Income

6. 40

17. 54

7. 30

Net Income

4. 29

10. 67

3. 57

Balance Sheet

Total Current Assets

139. 52

123. 95

95. 17

Total Assets

203. 79

184. 76

162. 68

Total Current Liabilities

63. 93

59. 96

54. 46

Total Liabilities

65. 46

62. 26

59. 91

Total Equity

138. 34

122. 50

102. 78

Cash Flow

Net Income/Starting Line

-

10. 67

3. 57

Cash from Operating

4. 49

23. 03

7. 08

Cash from Investing

3. 29

-5. 15

-6. 02

Cash from Financing

-2. 13

2. 21

-5. 43

Net Change in Cash

5. 93

19. 77

-4. 08

;

Key Stats ; Ratios

Quarterly

(Sep '06)

Annual

(2005)

Annual

(TTM)

Net Profit Margin

4. 13%

4. 26%

5. 24%

Operating Margin

8. 37%

7. 00%

8. 37%

EBITD Margin

-

10. 19%

10. 88%

<https://assignbuster.com/kendle-international-inc/>

Return on Average Assets

-

6.14%

-

Return on Average Equity

-

9.48%

-

Employees

1,900

-

-

However compared to the competition, the basic numbers are as follows:

Company

Revenue

Market Cap

EPS

PE Ratio

Beta

Quote

Kendle

250

503

1.15

30.48

<https://assignbuster.com/kendle-international-inc/>

2. 11

35. 05

<http://google.brand.edgar-online.com/fetchFilingFrameset.aspx?FilingID=4279576&Type=HTML>

Parexel

760

829

0. 87

35

0. 9

30. 7

Covance

1250

3920

2. 12

28. 9

0. 32

61. 25

Pharmaceutical Product Development

1037

3700

1. 33

23. 7

<https://assignbuster.com/kendle-international-inc/>

1. 19

31. 6

Pharmanet Development Group

429

427

-2. 22

10. 38

1. 52

23. 04

The Advisory Board Company

165

1. 09

1. 31

44

0. 53

57. 73

As an industry the companies enjoy a very high PE ratio.

The 10k Reports are available on Edgar online and also on the 10k wizard.